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Abstract
Background: Pancreatic adenocarcinoma comprises 85% of all cases of pancreatic malignancies. From a diagnostic
standpoint, these tumors are readily diagnosed by fine needle aspiration, with an accuracy of greater than 90%; however
it is often difficult to ascertain whether these are primary or metastatic in nature. This study was undertaken to see the
usefulness of CK19, CA19-9 and a newly described marker, SMAD4 in confirming the pancreatic origin of these tumors.
Briefly, SMAD4 (DPC4) is a tumor-suppressor gene located on chromosome 18q which has been shown to mediate the
downstream effects of TGF-β superfamily signaling, resulting in growth inhibition. The loss of SMAD4, which as been
reported to occur in 55% of pancreatic ductal adenocarcinomas may lead to up regulation of cell cycle proteins and hence
increase cellular proliferation. In addition, SMAD4 has been suggested to possibly have prognostic potential, with the
presence of SMAD4, indicating shorter survival after resection.
Design: Clinical data was reviewed to identify patients with proven, primary pancreatic adenocarcinoma. A total of 25
patients with diagnostic material from fine needle aspiration cell blocks, were retrieved from our files at Emory University
Hospital. In addition cell blocks from clinically diagnosed non-pancreatic adenocarcinomas were also selected as controls
for this study (10 cases of colonic adenocarcinoma, 10 cases of pulmonary adenocarcinoma, 10 cases of breast ductal
carcinoma and 10 cases of ovarian mucinous adenocarcinoma). Formalin fixed, paraffin-embedded sections from these
were stained with SMAD4, CK19, and CA19-9, using pressure cooker antigen retrieval, labeled polymer HRP (DAKO),
and the DAKO autostainer.
Results: Immunohistochemical staining was reviewed based on intensity (negative, low-positive, and high-positive) and
percentage of cells. In primary pancreatic ductal adenocarcinoma, CK 19 showed diffuse cytoplasmic positivity in 23 of
25 cases, CA 19-9 showed apical cytoplasmic staining in all 25 cases, and SMAD4 showed nuclear staining in 20 of 25
cases. In the control group comprising of non-pancreatic adenocarcinoma SMAD4 was negative (100%) in all 10 cases of
colonic and pulmonary adenocarcinoma. However 1 of 10 cases (10%) of breast and ovarian adenocarcinoma did show
low positivity nuclear staining. However the expression of CA19-9 and CK19 was more variable in these different non-
pancreatic malignancies.
Conclusion: Pancreatic adenocarcinoma showed positive immunohistochemical staining for SMAD4 in 80%, CK19 in
100% and CA19-9 in 100% of the selected cases. These markers, when used as a panel, may confirm the diagnosis of
pancreatic adenocarcinoma in fine needle aspiration samples, and help in differentiating from metastatic adenocarcinoma.
This may help in determination of appropriate surgical and chemotherapeutic options.
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Background
Neoplasia of the pancreas consists of a wide spectrum of
benign and malignant tumors, with pancreatic ductal ade-
nocarcinoma comprising 85% of malignant cases. The
American Cancer Society estimates that 33,730 new cases
of pancreatic cancer will be diagnosed in 2006; and
32,300 fatalities will be attributed to the disease [1].
Although rates of pancreatic cancer have slowly declined
in the United States over the past 15–25 years, it is the
fourth leading cause of cancer mortality [1], with a 5-year
survival rate of as low as 5% [2]. The poor prognosis of
pancreatic ductal adenocarcinoma is mainly attributed to
its insidious and inconspicuous growth often presenting
late in the clinical disease process. It is estimated that at
initial diagnosis of disease, approximately 50% of
patients will have distant metastases, while only 10% will
have tumors localized to the pancreas [3].
The incidence of pancreatic ductal adenocarcinoma
increases gradually with age, with approximately 80% of
cases diagnosed in individuals 60–80 years [4]. Males are
more likely than females to be diagnosed with pancreatic
cancer; and ethnic disparities exist, with African and Japa-
nese Americans having higher incidence and mortality
rates as compared to Anglo Americans [5]. Although the
exact cause of pancreatic cancer remains unknown, several
environmental and host factors have been shown to be
associated with the progression to malignant disease.
Among the risk factors investigated, smoking is the most
significant with smokers having a two-fold increased risk
of developing pancreatic cancer as compared to non-
smokers [6].
It is clinically very important, that a correct and accurate
diagnosis of primary pancreatic ductal adenocarcinoma
be rendered, and may require immunohistochemical
stains to exclude other known primaries. We selected
SMAD4, CA19-9 and CK 19 immunohistochemical stains
to help us in this endeavor. All three markers are expressed
in pancreatic adenocarcinoma and are uniformly negative
in pancreatic non-ductal neoplasms [7,8]. hence, they as a
panel may be very helpful in diagnosing pancreatic ductal
carcinoma, which is the premise and hypothesis for our
study.
Methods
A retrospective review of clinical data was evaluated
through a search of Emory University Hospital Laboratory
information systems to identify patients with proven, pri-
mary pancreatic adenocarcinoma. A total of twenty-five
patients with diagnostic material from CT guided fine nee-
dle aspiration, cell blocks collected from January 1, 2002
through December 31, 2005 were retrieved. All cases were
clinically a part of the Pancreatic tumor registry, with clin-
ically proven pancreatic adenocarcinoma, based on com-
bined clinical/radiologic and histologic data. In addition
cell blocks from clinically diagnosed non-pancreatic ade-
nocarcinomas were also selected as controls for this study
(10 cases of colonic adenocarcinoma, 10 cases of pulmo-
nary adenocarcinoma, 10 cases of breast ductal carcinoma
and 10 cases of ovarian mucinous adenocarcinoma). All
sections from the cells blocks were, formalin-fixed, paraf-
fin-embedded tissue (5 microns), and were tested for the
presence of SMAD4 (1:40, Novacastra, Newcastle on
Tyne), CK19 (1:50, DAKO, Carpinteria, CA), and CA 19-9
(1:200, Novacastra, Newcastle on Tyne), using a horserad-
ish peroxidase (HRP) labeled polymer and heat-induced
antigen retrieval. The DAKO ENVISION system was used,
which consists of a two step horseradish peroxidase
labeled polymer conjugated with secondary antibodies
(DAKO ENVISION System, DAKO Corp., Carpintera,
CA). This method was used in combination with the auto-
mated DAKO AUTOSTAINER (DAKO Corp.). Hematoxy-
lin was used as counter stain. Negative controls were
performed and consisted of primary antibody replaced by
buffer specific antibody absorbed with antigen.
Sections were deparfinnized and rehydrated. Antigen
retrieval was performed in citrate buffer (pH 6) using an
electric pressure cooker for 5 minutes at 120°C with cool-
ing for 10 minutes before immunostaining. All tissues are
then exposed to 3% hydrogen peroxide for 5 minutes, pri-
mary antibody for 30 minutes, labeled polymer HRP for
30 minutes, diaminobenzidine as chromogen for 5 min-
utes and DAKO automation hematoxylin as counter stain
for 15 minutes. All incubation steps were performed at
room temperature and between incubations, sections
were washed with Tris-buffered saline (TBS) solution.
Cover slipping was performed using the Tissue-Tek SCA
(Sakura Finetek USA, Inc., Torrance, CA) automatic cover-
slipper.
Results
Immunohistochemical staining, with appropriate positive
and negative controls, were reviewed independently by
two pathologists (MTS and CC). No interobserver discrep-
ancy was noted. A total of 25 pancreatic adenocarcinomas
were reviewed, of which 20 cases were poorly differenti-
ated adenocarcinoma, while 5 were moderately differenti-
ated adenocarcinoma. The reviewing pathologists
evaluated the tissue sections based on both the staining
intensity and percentage positivity of cells. The intensity
was graded as negative (no staining observed), low-posi-
tive (moderate degree of staining), and high-positive
(strong intense staining). There were twenty-five cases,
80% (20 of 25 cases) were positive for SMAD4, while
100% of the cases were positive for both CK 19 and CA19-
9. These findings are summarized in Table 1. SMAD4
staining is nuclear, with high staining intensity observed
in 11 (44%) of the cases. No cytoplasmic staining forCytoJournal 2007, 4:13 http://www.cytojournal.com/content/4/1/13
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SMAD4 was noted. Diffuse cytoplasmic staining was
noted for CK19 and a high staining intensity was observed
in 23 (92%) of the cases studied. CA19-9 displayed an
apical cytoplasmic staining and a high staining intensity
was observed in all 25 (100%) of the cases. Lastly, benign
pancreatic ductal epithelial cells were identified in 21 of
25 cases, benign pancreatic acinar cells were identified in
9 of 25 cases, and benign pancreatic islet cells were noted
in 11 of 25 cases and were uniformly negative for SMAD4,
CA19-9 and CK 19 immunohistochemical staining. In
view of these results the sensitivity for SMAD4 for pancre-
atic ductal adenocarcinoma is 80% while for CA19-9 and
CK19 it is 100%. The specificity for all three markers is
0%.
The results of the control group comprising of non-pan-
creatic adenocarcinoma are summarized in Table 2.
SMAD4 was negative (100%) in all 10 cases of colonic
and pulmonary adenocarcinoma. However, 1 of 10 cases
(10%) of breast and ovarian adenocarcinoma did show
low positivity nuclear staining. The expression of CA19-9
and CK19 was more variable in these different non-pan-
creatic malignancies and is further tabulated in Table 2.
Discussion
In 2006, a total of 33,730 new cases of pancreatic cancer
were identified according to American Cancer Society sta-
tistics [1]. In addition, for that same year the estimated
deaths from pancreatic cancer were 32,300 individuals
making it the fourth leading cause of cancer mortality [1].
Overall, these tumors are associated with a poor progno-
sis, and several studies have shown that the best predictor
of prolonged survival is complete surgical resection. Host
factors play an integral role in the development of pancre-
atic carcinoma. It is now well accepted that pancreatic car-
cinoma follows a progression of histological and
molecular changes leading to the development of malig-
nancy. Analogous to the sequence of colorectal carcinoma
from non-neoplastic epithelium to adenoma to invasive
carcinoma, pancreatic carcinoma also follows a similar
paradigm. It has been demonstrated that precursor lesions
known as pancreatic intraepithelial neoplasias (PanIN)
are associated with increasing degrees of cytological and
architectural atypia associated with the accumulation of
genetic alterations in cancer associated genes, ultimately
leading to malignancy. Among these genetic alterations,
K-ras activation and HER-2/neu expression appears to
occur relatively early, while p16 inactivation occurs at an
intermediate stage, and ultimately p53, BRCA2, and
SMAD4 (DPC4) inactivation occurs late in the disease
process [9].
SMAD4 or DPC4 (deleted in pancreatic cancer, locus 4) is
a tumor suppressor gene located on the long arm of chro-
mosome 18. It was first described in pancreatic cancer by
Harn et al. in 1996, who demonstrated that nearly 90% of
pancreatic cancers show loss of heterozygosity for this
gene [10,11]. SMAD4 has also been suggested to be genet-
ically responsible for familial juvenile polyposis and also
has been implicated as a late genetic event in colorectal
carcinogenesis [12]. SMAD4 is part of a group of SMAD
proteins that are an essential component of the TGFβ sig-
naling pathway, which negatively regulates the growth of
epithelial cells. More specifically, SMAD4 binds to other
SMAD proteins forming a complex, which interacts with
DNA binding proteins leading to regulation of transcrip-
tion and ultimately decreased cellular proliferation [12].
Thus, the loss of SMAD4 expression in pancreatic ductal
adenocarcinoma leads to upregulation of cell cycle pro-
teins and hence increases cellular proliferation.
CA19-9 or carbohydrate antigen 19-9 is a blood group
related antigen and is biochemically related to the Lewis A
blood group substance. CK19 is a cytokeratin which has
been described to show strong immunoreactivity in pan-
creatic adenocarcinoma in histologic sections, however,
its use in cell blocks from patients with pancreatic adeno-
carcinoma has not been previously described. The pur-
pose of our study was to assess the diagnostic utility of
SMAD4 along with CK19 and CA19-9 in confirming the
pancreatic origin of tumors.
Our study has demonstrated that the immunohistochem-
ical staining panel of SMAD4, CK19, and CA19-9 is useful
in confirming the diagnosis of pancreatic adenocarci-
noma. Twenty-five selected cases of clinically confirmed
pancreatic adenocarcinoma (see Figure 1) were evaluated
for all three markers, of which 80% of the cases stained
positive for SMAD4, while 100% of the cases were posi-
tive for CK19 and CA19-9. In regard to SMAD4 immuno-
Table 1: SMAD4, CK 19 and CA 19-9 in pancreatic tumor cell immunoreactivity is highlighted in this table.
SMAD4 CK19 CA19-9
Staining Pattern Nuclear Diffuse Cytoplasmic Apical Cytoplasmic
Negative 5 cases 0 cases 0 cases
Low Positive 9 cases 2 cases 0 cases
High Positive 11 cases 23 cases 25 cases
% Range of Positive cells Low Positive 60–80% & High Positive 40–90% Low Positive 80–90% & High Positive 95–100% High Positive 95–100%CytoJournal 2007, 4:13 http://www.cytojournal.com/content/4/1/13
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histochemical staining properties, our cases,
demonstrated a crisp nuclear staining pattern with virtu-
ally no cytoplasmic or background staining (Figure 2 and
5). SMAD4 showed a low positivity in 9 (36%) cases (Fig-
ure 5), with 60–80% of the tumor cells exhibiting immu-
noreactivity and the other additional 11 (44%) cases
showed a high positivity (Figure 2) with 40–90% of the
tumor cells exhibiting immunoreactivity. The non-pan-
creatic malignancies that were studied as a control group
(Table 2) also yielded the data that SMAD4 shows nega-
tive immunoreactivity in colonic and pulmonary adeno-
carcinoma, however in 10% of breast ductal and ovarian
mucinous adenocarcinoma, focal low positivity nuclear
staining may be observed.
The staining pattern for CK19 was diffuse cytoplasmic and
noted to be present in 100% of the cases (Figure 3). High
staining positivity was observed in 23 (92%) cases. This
study also showed that in addition to SMAD4 and CK19,
CA19-9 was also useful for confirming the diagnosis of
pancreatic adenocarcinoma. CA19-9 showed apical cyto-
plasmic staining in all 25 (100%) of our cases, with a
range of 95–100% of the tumor cells with high positivity
(Figure 4). The non-pancreatic control group (Table 2)
showed variable staining for both CA19-9 and CK19.
To our knowledge, this is the first time that SMAD4 stain-
ing in combination with CK19 and CA19-9 has been eval-
uated in pancreatic adenocarcinoma. The different
staining intensity noted in these three markers may be
attributed to labeling of proteins at a different phase of
pathogenesis of pancreatic adenocarcinoma. Among
other primary pancreatic neoplasm, Cao et al demon-
strated that in contrast to pancreatic adenocarcinomas
that show loss of SMAD4 protein in 55% of cases, loss of
SMAD4 expression is absent in pancreatic nonductal neo-
plasms [7]. In addition, prior studies have demonstrated
the presence of SMAD4 genetic alterations among colorec-
tal carcinoma [12] and cholangiocarcinoma [13] in only
11–17% and 45.2% of cases, respectively. Taken together,
these studies suggest that SMAD4 expression is highly use-
ful in diagnosing pancreatic adenocarcinoma.
Representative fragment of Pancreatic Adenocarcinoma  stained with CK19 (IHC, 40×) Figure 3
Representative fragment of Pancreatic Adenocarcinoma 
stained with CK19 (IHC, 40×).
Representative fragment of Pancreatic Adenocarcinoma  (H&E, 40×) Figure 1
Representative fragment of Pancreatic Adenocarcinoma 
(H&E, 40×).
Table 2: SMAD4, CK 19 and CA 19-9 immunoreactivity in non-




0 of 10 cases 4 of 10 cases 6 of 10 cases
Pulmonary 
adenocarcinoma
0 of 10 cases 5 of 10 cases 3 of 10 cases
Breast ductal 
carcinoma
1 of 10 cases 7 of 10 cases 3 of 10 cases
Ovarian mucinous 
adenocarcinoma
1 of 10 cases 8 of 10 cases 7 of 10 cases
Representative fragment of Pancreatic Adenocarcinoma  stained with SMAD4 showing high positivity (IHC, 40×) Figure 2
Representative fragment of Pancreatic Adenocarcinoma 
stained with SMAD4 showing high positivity (IHC, 40×).CytoJournal 2007, 4:13 http://www.cytojournal.com/content/4/1/13
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The concept that SMAD4 expression may correlate with
prognosis, is also of interest. Biankin et al. evaluated 348
patients with pancreatic adenocarcinoma and demon-
strated that tumor size (greater than 4.5 cm), resection
margin involvement, and perineural invasion were inde-
pendent prognostic factors [14]. Far more interesting
however, was the finding that SMAD4 expression within
excised pancreatic carcinoma was associated with a worse
outcome. They demonstrated that loss of SMAD4 expres-
sion was associated with a favorable prognosis (median
survival, 13.6 vs 6.4 months; logrank, P = 0.257). The
advantage of SMAD4 expression as a prognostic indicator
is that it is potentially assessable preoperatively in com-
parison to tumor size, resection margins, perineural inva-
sion, and lymph node metastasis, which can only be
accurately evaluated after surgery. In our own study, 18 of
the 20 patients with SMAD4 positivity died within 6
months of diagnosis and 2 (low positivity SMAD4 expres-
sion) of the 20 patients were still alive 7 and 9 months
after diagnosis of pancreatic adenocarcinoma. The 5
patients who were negative for SMAD4 expression died
between 11 and 13 months after diagnosis of pancreatic
adenocarcinoma. In view of this data, ultimately in the
future, preoperative evaluation of SMAD4 status may help
in determining appropriate surgical and chemotherapeu-
tic options.
In summary, our study shows that SMAD4, CK19 and
CA19-9 are helpful markers for confirming the diagnosis
of primary pancreatic ductal carcinoma. Also, showing
that fine needle aspiration is an excellent diagnostic
modality for obtaining samples for diagnosing primary
malignancies in the pancreas and if need be, usage of the
studied immunohistochemical stains would help in con-
firming this diagnosis.
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